Glucosamine sulfate

Rising Prevalence of Osteoporosis, Growth of Geriatric Population and Increasing Awareness Regarding Preventive Healthcare are Fueling Demand for Calcium, Vitamin D, Collagen and Glucosamine Global Market: Ken Research PORTLAND, Ore., April 28, 2026 /PRNewswire/ -- Allied Market Research published a new report entitled "Bone Health Supplements Market by Type (Vitamins, Calcium, Collagen Omega-3, Glucosamine and Others), Dosage Form (Tablets Capsules Powder and Others) And Distribution Channel (Pharmacies Drug Stores Supermarkets Hypermarkets Online Providers and Others): Global Opportunity Analysis and Industry Forecast 2025–2034" full report for free: It provides a comprehensive understanding of the global bone health supplements market dynamics, trends, major growth drivers, competitive landscape and actionable investment opportunities. Market Size & Growth Global Bone Health Supplements Market to Reach $23.1 Billion by 2034 The global Bone health supplements market in 2024 was worth $13.8 Bn and is projected to reach a reserve of$23.1 Bn by 2034, growing at a CAGR of over5.3percent from 2025–2034. Such considerable growth path further indicates a global paradigm shift toward preventive nutrition, proactive skeletal health management and increasing physician recommended supplementation protocols especially for aging population groups and postmenopausal women. World-wide in 2019 and estimated178 million new fractures (33.4% increase from 1990) occurred, and a total of455 million prevalent fracture cases (70.1% growth since 1990), according to the World Health Organization (WHO,2024). The rise since 1990 is reflected by the fact that fragility fractures alone contributed to 25.8 million years lived with disability (YLDs). A new NCBI study (2025) further estimated that there are 41.5 million new osteoporosis cases around the world in 2019, and total cases are projected to be a staggering 263.2 million by 2030–2034. These alarming statistics highlight the global, urgent and sustained need for preventative supplementation for bone health. Request Sample of the Report on bone health supplements market: Key Market Insights Epidemiological, demographic and consumer behavior trends continue to converge to drive the growth of the bone health supplements market: A new study project by Visiongain with a long-term forecast period from 2022 to 2032 shows that several factors continue to drive industry expansion - Surging Osteoporosis & Bone Disorder Burden The increasing prevalence of osteoporosis, osteopenia and fragility fractures which are related to aging is the primary driver of growth. The WHO and NCBI studies, which both suggest that bone-related diseases still account for a significant proportion of global disability and healthcare expenditure In-depth analysis of the global Bone Health Supplements market sectors by another geographical region, with an explanation of growth trends & opportunities to 2030The report provides information regarding the high-growth markets, key regions, and their respective growth forecasts over the projected timeframe Growing Aging Global Population: The geriatric population (individuals aged over 60) is expected to grow from approximately 1.4 billion worldwide in 2030 according to the WHO which represents the largest growing consumer base for bone health supplements like calcium & vitamin D, magnesium & collagen peptides. Medico Endorsement & Preventive Healthcare Trends →Global physicians and organization endorse calcium and vitamin D supplementation for postmenopausal women & elderly patients at high risk of fractures. That professional backing goes a long way toward driving market adoption. Increasing Bone Health Awareness: The trend of consumer awareness on the necessity of bone density, joint mobility and long-term quality of life has spurred demand for ever-prominent bone support supplements — even in active millennials. E-Commerce & Direct-to-Consumer Growth The expansion of online sales channels has made ordering from a wider array of supplement formulations statistically easier, as storied brands and budding nutraceutical businesses can now deliver their products within arm's reach to consumers around the world. Want to Explore More, Connect to our Analyst - Market Segmentation The bone health supplements market is categorized by type, dosage form, and distribution channel. By Type: The calcium segment accounted for the largest revenue share in 2024, driven by its proven role in maintaining bone density, recommendation by healthcare professionals across multiple regions and high affordability among consumers across both developed and emerging markets. Worldwide, calcium supplements still stand as the pillar for both osteoporosis prevention and bone mineralization protocols. In contrast, the glucosamine subsection is predicted to gain the highest CAGR through 2025–2034 due to increasing acceptance of joint care solutions and rising cases of osteoarthritis, as well as higher demand for supplements supporting mobility in older people. Monthly sales for other product types are also worth noting, particularly: Vitamins (especially vitamin D and K2), Collagen Peptides, Omega-3 fatty acids, Magnesium and trace minerals. By Dosage Form: In 2024, tablets led the dosage form segment as a preferred option because they are easy to use and provide accurate dosing, stable product for longer periods of time, and cost-effective than other formats. Tablet-based manufacturing is scalable and production volume friendly, which makes them a favorite manufacturer. The 'Others' segment, including emerging formats like Gummies, Jelly Strips and new delivery systems, is projected to witness the fastest CAGR on account of demand for better tasting and innovative supplement formats. The refined encapsulation technologies manufacturing capsules also contribute to their market traction driven by increased bioavailability. By Distribution Channel: In 2024, supermarkets and hypermarkets retained their leading position as the distribution channel due to easy product availability combined with consumers being more likely to be tempted into impulse-purchasing. Nevertheless, the online providers segment is expected to be the fastest-growing growing segments during the forecast period due to an increase in e-commerce penetration rates, subscription-based supplement models, demand for direct-to-consumer brands as well as convenience shopping and digital health purchasing. Pharmacies and drug stores still capture one of the largest portions due to both inbound traffic from physician recommendations and a purchasing behavior that is often trust-based. Regional Insights North America (Dominating): North America accounted for the largest revenue share in 2024, attributed to high osteoporosis burden, greater consumer awareness of preventive healthcare and higher physician recommendation rates for calcium and vitamin D supplementation. Scoring high in the region is the United States, thanks to mature healthcare infrastructure, an engaged consumer audience with a penchant for wellness culture, a presence of an established nutraceutical industry, and higher availability via e-commerce and retail. Europe (The Second Fastest Market) - Europe with the second-highest market proportion supported by public health campaigns on bone health, the quickly aging population, and a strong emphasis on preventive care protocols. Supplement consumption is particularly high in Germany, the United Kingdom and France, where physicians often include bone health supplementation in standard osteoporosis prevention regimens. Asia-Pacific (Fastest-Growing Region)The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period due to rapid increase in geriatric population, rising healthcare costs, increasing awareness about bone health supplementation and aggressive penetration of global players in high-growth markets such as China, India and Japan. India capture over36% of the growth impetus from increase in prevalence of Osteoporosis and Japan's adoption of nutritional supplement as lifestyle Westernization drives demand. Latin America // Middle East/Africa: These are new markets of opportunity with increasing healthcare investment, improving supplement distribution networks, and growing middle-class populations prioritizing preventive nutrition fuelling near-term growth. Key Players The global bone health supplements market is fragmented at the top with a mixture of long-standing pharmaceutical behemoths, vertically integrated nutraceutical firms, and nimble direct-to-consumer brands. Allied Market Research report profiles key players in the global riding lawn mowers market. Amway (Nutrilite) Bayer AG Abbott Laboratories Haleon Plc. (Caltrate, Centrum) Nestlé S.A. (Nestlé Health Science) Nutramax Laboratories, Inc. Kirin Holdings / Blackmores Herbalife Otsuka Holdings Co. Ltd. (Pharmavite) NOW Foods Some of the strategies being adopted by these players include product launches, acquisitions, geographic expansion, clinical validation for ingredients used in bone health supplements and multi-channel distributions to cement their global position in the bone health supplements market. A competitive landscape based on innovation emerges with the presence of big pharma companies such as Bayer AG, consumer health leaders such as Haleon and specialist nutrition players. For Purchase Related Queries/Inquiry - Key Recent Industry Developments May 2025 - Haleon: As part of it's strategy to build the largest portfolio of calcium supplement delivery systems in the Philippines and launched premium Centrum Daily Wellness Packs in South Korea to align with faster consumer growth within 'super premium' segments as a response to increasing concerns over rising levels of calcium deficiency across Asia. As seen in March - April 2025, the debut of HydroxyBMD3, Juvents next-generation bone health supplement at Bone Health & Osteoporosis Foundation (BHOF) Annual Symposium in Washington, D.C. solidified innovation for clinically validated bone density support solutions. Herbalife (March 2025) - A company looking to purchase a personalized nutrition company, highlighting market movement toward custom, data-driven supplementation solutions for people with their own bone health profile. February 2024 New-Edge Nutritional Food Solutions to Target Active Millennial Consumers Released Resource Activ Nestlé Health Science released the product to capture the spirit of current active millennial consumers and reflect the market's evolution beyond providing products strictly for elderly users. September 2022 - Abbott Laboratories: Launched Ensure with HMB (Hydroxy-Methyl butyrate) in India, a professional adult nutrition supplement that promotes bone and muscle health, which indicates an emphasis on the penetration of emerging markets. February 2022 - Amway India: Introduced a new offering of Nutrilite in jelly strip and gummy delivery formats, driven by rising consumer interest for fresh, palatability-first ideation in the bone health category. Access the full bone health supplements market analysis report here: Analyst Review The bone health supplements market is now at a crucial inflection point, as preventative nutrition becomes mainstream healthcare policy priority. With an aging world population coupled with increasing osteoporosis burden, physician supported supplement adoption, and a raw explosion of direct-to-consumer nutraceutical brands this market is poised for steady and substantial growth well into the next decade. YOU MAY ALSO BE INTERESTED IN Revolution of Bone Health Supplement Delivery The digital health revolution and innovations in supplement delivery formats from advanced encapsulation to functional gummies are transforming the accessibility and interactively of bone health products for consumers. Over the counter (OTC) glucosamine-based supplements and such emerging compounds as vitamin K2 and marine collagen are in line to be the next major catalyst for growth among market participants. Trending Reports in Healthcare Industry: Light Therapy Market - Global Opportunity Analysis and Industry Forecast, 2024-2035 Pediatric Ultrasound Market - Global Opportunity Analysis and Industry Forecast, 2024-2035 Medical Imaging Informatics Market - Global Opportunity Analysis and Industry Forecast, 2024-2035 Respiratory Inhaler Devices Market - Global Opportunity Analysis and Industry Forecast, 2024-2035 Bone Regeneration Market - Global Opportunity Analysis and Industry Forecast, 2024-2035 Medical Device Packaging Market - Global Opportunity Analysis and Industry Forecast, 2024-2035 Hyaluronic Acid Products Market - Global Opportunity Analysis and Industry Forecast, 2024-2035 Get access to the library of reports at any time from any device and anywhere. For more details, follow the link: About Allied Market Research: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients in making strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI. We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality data and help clients in every way possible to achieve success. Every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact David Correa 1209 Orange Street, Corporation Trust Center, Wilmington, New Castle, Delaware 19801 USA. Toll Free: +1-800-792-5285 Int'l: +1-503-894-6022 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1-855-550-5975 [email protected] Logo: SOURCE Allied Market Research 21% more press release views with Request a Demo

本周药品注册受理数据，分门别类呈现，一目了然。(4.20-4.26） 新药上市申请 药品名称 企业 注册分类 受理号 醋酸索乐匹尼布片 和记黄埔医药(上海)有限公司 1 CXHS2600058 HL231吸入溶液 四川海思科制药有限公司 2.2 CXHS2600060 布地奈德福莫特罗吸入粉雾剂(IV)胶囊型 杭州畅溪制药有限公司 2.2 CXHS2600059 司美格鲁肽注射液 江苏诺泰澳赛诺生物制药股份有限公司 2.2 CXHS2600057 司美格鲁肽注射液 江苏诺泰澳赛诺生物制药股份有限公司 2.2 CXHS2600056 司美格鲁肽注射液 江苏诺泰澳赛诺生物制药股份有限公司 2.2 CXHS2600055 司美格鲁肽注射液 江苏诺泰澳赛诺生物制药股份有限公司 2.2 CXHS2600054 柯美奇拜单抗注射液 上海麦济医药有限公司 1 CXSS2600071 艾帕洛利托沃瑞利单抗注射液 齐鲁制药有限公司 2.2 CXSS2600072 新药临床申请 药品名称 企业 注册分类 受理号 DZ-002注射液 深圳市伟航奕宁生物科技有限公司 1 CXHL2600502 HRS-1780 片 山东盛迪医药有限公司 1 CXHL2600501 HRS-1780 片 山东盛迪医药有限公司 1 CXHL2600500 BW-50920注射液 上海舶望制药有限公司 1 CXHL2600504 BIOS0629-109片 杭州百诚医药科技股份有限公司 1 CXHL2600498 BIOS0629-109片 杭州百诚医药科技股份有限公司 1 CXHL2600497 HS-20136-2注射液 江苏豪森药业集团有限公司 1 CXHL2600491 HS-20136-2注射液 江苏豪森药业集团有限公司 1 CXHL2600490 HS-20136-2注射液 江苏豪森药业集团有限公司 1 CXHL2600489 HS-20136-2注射液 江苏豪森药业集团有限公司 1 CXHL2600488 伊匹乌肽雾化吸入溶液 广州益明康生物科技有限公司 1 CXHL2600499 BPR-30160639注射液 成都倍特锐玛生物医药科技有限公司 1 CXHL2600503 CMS-D017胶囊 海南康哲维盛科技有限公司 1 CXHL2600496 CMS-D017胶囊 海南康哲维盛科技有限公司 1 CXHL2600495 S241656片 施维雅(北京)医药研发有限公司 1 CXHL2600494 S241656片 施维雅(北京)医药研发有限公司 1 CXHL2600493 S241656片 施维雅(北京)医药研发有限公司 1 CXHL2600492 SNH-118110软胶囊 赛诺哈勃药业(成都)有限公司 1 CXHL2600487 SNH-118110软胶囊 赛诺哈勃药业(成都)有限公司 1 CXHL2600486 GenSci144片 长春金赛药业有限责任公司 1 CXHL2600476 GenSci144片 长春金赛药业有限责任公司 1 CXHL2600475 IN10018片 应世生物科技(深圳)有限公司 1 CXHL2600474 IN10018片 应世生物科技(深圳)有限公司 1 CXHL2600473 GT818胶囊 标新生物医药科技(上海)有限公司 1 CXHL2600483 GT818胶囊 标新生物医药科技(上海)有限公司 1 CXHL2600482 BG-75202片 百济神州(苏州)生物科技有限公司 1 CXHL2600463 CMS-F021凝胶 海南德镁医药科技有限责任公司 1 CXHL2600472 CMS-F021凝胶 海南德镁医药科技有限责任公司 1 CXHL2600471 CMS-F021凝胶 海南德镁医药科技有限责任公司 1 CXHL2600470 BG-75202片 百济神州(苏州)生物科技有限公司 1 CXHL2600465 BG-75202片 百济神州(苏州)生物科技有限公司 1 CXHL2600464 BN114723 山东百诺医药股份有限公司 2.2 CXHL2600481 BN114723 山东百诺医药股份有限公司 2.2 CXHL2600480 BN114723 山东百诺医药股份有限公司 2.2 CXHL2600479 HY-1016缓释注射液 四川汇宇海玥医药科技有限公司 2.2 CXHL2600469 HY-1016缓释注射液 四川汇宇海玥医药科技有限公司 2.2 CXHL2600468 HY-1016缓释注射液 四川汇宇海玥医药科技有限公司 2.2 CXHL2600467 HY-1016缓释注射液 四川汇宇海玥医药科技有限公司 2.2 CXHL2600466 甘糖酯片 青岛国信制药有限公司 2.4 CXHL2600485 甘糖酯片 青岛国信制药有限公司 2.4 CXHL2600484 无水乙醇注射液 国药集团国瑞药业有限公司 2.4 CXHL2600477 马来酸奈拉替尼片 甫康生物科技(上海)股份有限公司 2.4 CXHL2600478 重组带状疱疹疫苗(CHO细胞) 四川明瑞佳生物科技有限公司 1.3 CXSL2600443 注射用MST-168单抗 慕宝盛科生物医药(广东横琴)有限公司 1 CXSL2600444 BA1106注射液 山东博安生物技术股份有限公司 1 CXSL2600439 SHR-8203注射液 北京盛迪医药有限公司 1 CXSL2600437 UX-DA003注射液 上海跃赛生物科技有限公司 1 CXSL2600438 注射用IMM2510S 宜明昂科生物医药技术(上海)股份有限公司 1 CXSL2600432 注射用IPN60300 益普生(上海)医药科技有限公司 1 CXSL2600434 注射用ZHB130 江苏众红生物工程创药研究院有限公司 1 CXSL2600436 注射用ESG406 上海诗健生物科技有限公司 1 CXSL2600433 注射用SKB315 四川科伦博泰生物医药股份有限公司 1 CXSL2600431 RGL-185注射液 上海瑞宏迪医药有限公司 1 CXSL2600435 注射用BL-B01D1 成都百利多特生物药业有限责任公司 1 CXSL2600428 HMBD-001 上海贺维斯特医药科技有限公司 1 CXSL2600427 LY01015注射液 山东博安生物技术股份有限公司 2.2 CXSL2600441 LY01015注射液 山东博安生物技术股份有限公司 2.2 CXSL2600440 注射用重组A型肉毒毒素(Sf9细胞,150 kD天然氨基酸序列) 苏州若弋生物科技有限公司 2.4 CXSL2600429 注射用重组A型肉毒毒素(Sf9细胞,150 kD天然氨基酸序列) 苏州若弋生物科技有限公司 2.4 CXSL2600430 仿制药申请 药品名称 企业 注册分类 受理号 注射用硫酸多黏菌素B 河北圣雪大成制药有限责任公司 3 CYHS2600966 二羟丙茶碱注射液 江苏福邦药业有限公司 3 CYHS2600944 度米芬含片 合肥启旸生物医药科技有限公司 3 CYHS2600940 盐酸伐地那非口崩片 安徽圣鹰药业有限公司 3 CYHS2600958 米诺地尔泡沫剂(男用) 山西振东安欣生物制药有限公司 3 CYHS2600956 琥珀酸亚铁片 昆明源瑞制药有限公司 3 CYHS2600954 重酒石酸去甲肾上腺素注射液 河北科源药业有限公司 3 CYHS2600955 硝普钠注射液 扬州中宝药业股份有限公司 3 CYHS2600947 盐酸屈他维林片 江西亿友药业有限公司 3 CYHS2600928 布瑞哌唑口崩片 河北龙海药业股份有限公司 3 CYHS2600937 布瑞哌唑口崩片 河北龙海药业股份有限公司 3 CYHS2600936 艾司奥美拉唑镁肠溶胶囊 桂林华信制药有限公司 3 CYHS2600920 艾司奥美拉唑镁肠溶胶囊 桂林华信制药有限公司 3 CYHS2600919 磷酸奥司他韦颗粒 宁波美诺华天康药业有限公司 3 CYHS2600921 阿仑膦酸钠口服溶液 北京海晶生物医药科技有限公司 3 CYHS2600916 西格列汀二甲双胍缓释片 杭州和泽坤元药业有限公司 3 CYHS2600923 盐酸曲唑酮片 三金集团湖南三金制药有限责任公司 3 CYHS2600911 黄体酮注射液 湖南先施制药有限公司 3 CYHS2600910 依巴斯汀口服溶液 翎耀生物科技(上海)有限公司 3 CYHS2600909 酮洛芬贴剂 北京福元医药股份有限公司 3 CYHS2600915 酮洛芬贴剂 北京福元医药股份有限公司 3 CYHS2600914 盐酸头孢卡品酯颗粒 湖南科伦制药有限公司 4 CYHS2600965 维生素B12滴眼液 北京汇恩兰德制药股份有限公司 4 CYHS2600964 聚乙烯醇滴眼液 上海小方制药股份有限公司 4 CYHS2600963 乌帕替尼缓释片 安徽万邦医药科技股份有限公司 4 CYHS2600962 ω-3脂肪酸乙酯90软胶囊 山东禾琦制药有限公司 4 CYHS2600961 甲苯磺酸尼拉帕利胶囊 南京正大天晴制药有限公司 4 CYHS2600946 达格列净二甲双胍缓释片(III) 山西宝泰药业有限责任公司 4 CYHS2600943 达格列净二甲双胍缓释片(II) 山西宝泰药业有限责任公司 4 CYHS2600942 达格列净二甲双胍缓释片(I) 山西宝泰药业有限责任公司 4 CYHS2600941 枸橼酸钠血滤置换液 哈尔滨三联药业股份有限公司 4 CYHS2600939 氨甲环酸片 江苏福邦药业有限公司 4 CYHS2600960 二十碳五烯酸乙酯软胶囊 山东禾琦制药有限公司 4 CYHS2600959 注射用盐酸万古霉素 南京海纳制药有限公司 4 CYHS2600957 小儿法罗培南钠颗粒 国药集团致君(深圳)坪山制药有限公司 4 CYHS2600953 铝碳酸镁咀嚼片 广东彼迪药业有限公司 4 CYHS2600952 硫酸氢氯吡格雷片 四川新斯顿制药股份有限公司 4 CYHS2600950 琥珀酰明胶电解质醋酸钠注射液 南京正大天晴制药有限公司 4 CYHS2600949 盐酸奥布卡因滴眼液 润尔眼科药物(广州)有限公司 4 CYHS2600945 阿布昔替尼片 常州制药厂有限公司 4 CYHS2600932 阿布昔替尼片 常州制药厂有限公司 4 CYHS2600931 阿布昔替尼片 常州制药厂有限公司 4 CYHS2600930 吡美莫司乳膏 山西泽辰医药科技有限公司 4 CYHS2600929 尼莫地平片 烟台鲁银药业有限公司 4 CYHS2600927 枸橼酸氢钾钠颗粒 沈阳欣瑞制药有限公司 4 CYHS2600925 克立硼罗软膏 山东方明药业集团股份有限公司 4 CYHS2600938 巴瑞替尼片 安徽泰恩康制药有限公司 4 CYHS2600935 达格列净片 湖北广济药业股份有限公司 4 CYHS2600934 达格列净片 湖北广济药业股份有限公司 4 CYHS2600933 莫匹罗星软膏 德全药品(江苏)股份有限公司 4 CYHS2600951 注射用替考拉宁 山西威奇达光明制药有限公司 4 CYHS2600922 沙库巴曲缬沙坦钠片 沂南力诺制药有限责任公司 4 CYHS2600918 沙库巴曲缬沙坦钠片 沂南力诺制药有限责任公司 4 CYHS2600917 依达拉奉右莰醇注射用浓溶液 山东新时代药业有限公司 4 CYHS2600926 富马酸依美斯汀滴眼液 江苏远恒药业有限公司 4 CYHS2600924 达格列净二甲双胍缓释片(I) 新石阳光药业(河北)有限公司 4 CYHS2600904 氧 久策气体(将乐)有限公司 4 CYHS2600903 硫酸氨基葡萄糖胶囊 山东益健药业有限公司 4 CYHS2600908 达格列净二甲双胍缓释片(I) 新石阳光药业(河北)有限公司 4 CYHS2600907 达格列净二甲双胍缓释片(Ⅲ) 新石阳光药业(河北)有限公司 4 CYHS2600905 氧(液态) 久策气体(将乐)有限公司 4 CYHS2600902 艾拉莫德片 山西同达药业有限公司 4 CYHS2600901 苯磺酸氨氯地平片 山东益健药业有限公司 4 CYHS2600900 苯磺酸氨氯地平片 山东益健药业有限公司 4 CYHS2600899 盐酸氮卓斯汀鼻喷雾剂 北京京丰制药集团有限公司 4 CYHS2600898 磷酸芦可替尼片 浙江海正药业股份有限公司 4 CYHS2600913 丙戊酸钠缓释片 南京泽恒医药技术开发有限公司 4 CYHS2600912 达格列净二甲双胍缓释片(IV) 新石阳光药业(河北)有限公司 4 CYHS2600906 复方电解质注射液 辰欣药业股份有限公司 4 CYHS2600897 盐酸奥昔布宁洗剂 湖南派格兰药业有限公司 3 CYHL2600056 盐酸氢吗啡酮片 宜昌人福药业有限责任公司 3 CYHL2600055 盐酸氢吗啡酮片 宜昌人福药业有限责任公司 3 CYHL2600054 人血管性血友病因子 华润博雅生物制药集团股份有限公司 3.2 CXSL2600442 进口申请 药品名称 企业 注册分类 受理号 乌帕替尼缓释片 AbbVie Deutschland GmbH & Co. KG 2.4 JXHS2600042 奥妥珠单抗注射液 Roche Pharma (Schweiz) AG 2.2 JXSS2600040 AZD2265 AstraZeneca AB 1 JXHL2600118 LOU064片 Novartis Pharma AG 2.4 JXHL2600117 LY4298445注射液 Eli Lilly and Company 1 JXSL2600103 Denikitug Gilead Sciences, Inc. 1 JXSL2600101 Denikitug Gilead Sciences, Inc. 1 JXSL2600100 Tarlatamab(皮下注射) Amgen Inc. 2.1 JXSL2600102 中药相关申请 药品名称 企业 注册分类 受理号 筋骨草总环烯醚萜苷片 北京康辰药业股份有限公司 1.2 CXZS2600021 筋骨草总环烯醚萜苷 辽宁沃华康辰医药有限公司 1.2 CXZS2600020 芍药甘草汤颗粒 安徽协和成制药有限公司 3.1 CXZS2600022 清润养目颗粒 上海医药集团中药研究所有限公司 1.1 CXZL2600037 注：绿色字体部分为潜在首仿品种； 咸达数据2026年1月每月药讯已出！ 关注“咸达数据”，微信关键词回复 ” 年+月，如202601” 获得最新药迅！ 不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。